Stockscreener 앱 받기
9.80
0.41%
-0.04
시간 외 거래:
9.94
0.14
+1.43%
전일 마감가:
$9.84
열려 있는:
$9.96
하루 거래량:
391.36K
Relative Volume:
0.41
시가총액:
$2.56B
수익:
$7.94B
순이익/손실:
$225.54M
주가수익비율:
29.71
EPS:
0.3299
순현금흐름:
$709.16M
1주 성능:
-3.45%
1개월 성능:
-2.97%
6개월 성능:
+18.36%
1년 성능:
+11.87%
1일 변동 폭
$9.79
$9.96
1주일 범위
$9.79
$10.22
52주 변동 폭
$6.19
$11.14
그리폴스 Stock (GRFS) Company Profile
GRFS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
9.80 | 6.70B | 7.94B | 225.54M | 709.16M | 0.3299 |
|
LLY
Lilly Eli Co
|
734.17 | 659.82B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.79 | 425.05B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
208.06 | 368.08B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.89 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.07 | 212.29B | 63.43B | 16.42B | 14.72B | 6.49 |
그리폴스 Stock (GRFS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 재개 | Morgan Stanley | Overweight |
| 2024-03-12 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-04-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2023-01-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-04-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-10-19 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2021-10-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-06-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2021-04-20 | 개시 | Deutsche Bank | Hold |
| 2021-03-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2020-10-01 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-06-09 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-06-09 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-03-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-06-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-02-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2018-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-06-01 | 개시 | Barclays | Overweight |
| 2017-10-31 | 개시 | Citigroup | Buy |
| 2017-06-30 | 다운그레이드 | Goldman | Buy → Neutral |
| 2017-04-06 | 개시 | BofA/Merrill | Buy |
| 2017-01-03 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-02-09 | 업그레이드 | Berenberg | Hold → Buy |
| 2016-01-04 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2015-11-20 | 다운그레이드 | Berenberg | Buy → Hold |
| 2015-04-28 | 다운그레이드 | Berenberg | Buy → Hold |
모두보기
그리폴스 주식(GRFS)의 최신 뉴스
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
CNH Industrial NV (NYSE: CNH) Stock Forecast: Bearish Sentiment Points To -15.21% Downside In 2025 - stocksregister.com
Oppenheimer Asset Management Inc. Acquires 23,980 Shares of Grifols, S.A. (NASDAQ:GRFS) - Defense World
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SMRT’s latest rating updates from top analysts. - knoxdaily.com
Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com
Investing in Apellis Pharmaceuticals Inc (APLS) Is Getting More Attractive - knoxdaily.com
A company insider recently sold 10,000 shares of News Corp [NWSA]. Should You also Consider to Sale? - knoxdaily.com
Raymond James Downgrades Truist Financial Corporation (TFC) to a Mkt perform from an Outperform - knoxdaily.com
AT&T, Inc (T) rating upgrades by Exane BNP Paribas - knoxdaily.com
Grifols SA ADR (GRFS) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Lazard Inc (LAZ) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Can Verra Mobility Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
RYAN’s Market Whiplash: 0.32% YTD Rise, -10.03% Plunge in 30 Days - investchronicle.com
A significant driver of top-line growth: Grifols SA ADR (GRFS) - Sete News
SpringWorks Therapeutics Inc (SWTX) Stock: From Low to High in 52 Weeks - investchronicle.com
There is no doubt that Coeur Mining Inc (CDE) ticks all the boxes. - Sete News
GRFS (Grifols SA ADR) may reap gains as insiders became active recently - knoxdaily.com
BHP’s latest rating updates from top analysts. - knoxdaily.com
FHN’s latest rating updates from top analysts. - knoxdaily.com
Lake Street’s latest rating for ORGO stock - knoxdaily.com
Fox Corporation [FOX] stock was sold by MURDOCH KEITH RUPERT at the price of US$3.08 million - knoxdaily.com
6 undervalued stocks with low beta - Morningstar Australia
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - PR Newswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. - GlobeNewswire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, - GlobeNewswire
Grifols sees China stake sale going ahead despite Gotham City report - Reuters
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Novo Nordisk A/s Dividend History & Dividend Yield 2024 - INDmoney
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - Newswire Canada
그리폴스 (GRFS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.38%
0.60%
자본화:
|
볼륨(24시간):